Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SK Chemicals","sponsor":"AriBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Announces Completion of Enrollment in Phase 2 Alzheimer\u2019s Study with AR1001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Standigm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA\u2019s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Approval of COVID-19 Vaccine SKYCovion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Tiumbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by SK Chemicals

    Menu

    SK Chemicals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SK Chemicals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data

              Details:

              The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.

              Lead Product(s): Merigolix

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Tiumbio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Private Placement December 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SK Chemicals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Regulatory Approval of COVID-19 Vaccine SKYCovion

              Details:

              SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.

              Lead Product(s): Recombinant Adjuvanted Covid-19 Vaccine,AS03

              Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovion

              Highest Development Status: Approved Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SK Chemicals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EMA’s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine

              Details:

              Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.

              Lead Product(s): SARS-CoV-2 Surface Spike Protein,Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Skycovion

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SK Chemicals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate

              Details:

              The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Recipient: Standigm

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SK Chemicals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001

              Details:

              AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.

              Lead Product(s): Methylbenzylamine

              Therapeutic Area: Neurology Product Name: AR1001

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: AriBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY